CTLA4 and rheumatoid arthritis: One variant (rs3087243) had high evidence of colocalisation (PP4 = 1) and is in close proximity (<200 bp) from gene CTLA4. CTLA4 is a target for FDA-approved drugs used to treat several cancers (e.g., ipilimumab) and Rheumatoid arthritis (abatacept).